Key result
Mechanical thrombectomy use doubles to ~12% in young ischemic stroke, yet in-hospital mortality remains stable.
Why the study?
Ischemic stroke incidence in young adults is increasing, and although reperfusion therapies like mechanical thrombectomy have transformed stroke care, their impact on mortality in this low-risk population remained uncertain.
Does the expansion of reperfusion therapies, particularly mechanical thrombectomy, reduce in-hospital mortality in young adults (aged 18-50 years) hospitalized with ischemic stroke?
Observational (n=20,533)
Yes
Does the expansion of reperfusion therapies, particularly mechanical thrombectomy, reduce in-hospital mortality in young adults (aged 18-50 years) hospitalized with ischemic stroke?
Despite a near doubling of mechanical thrombectomy use between 2016 and 2022 among young adults with ischemic stroke in Spain, in-hospital mortality remained unchanged at 2.8% and was primarily driven by comorbidities such as malignant neoplasm and acute organ complications.
Answers are grounded in this paper and cite their sources.
Stable mortality despite rising mechanical thrombectomy use warrants prospective trials; leaves open net benefit in young adults.
BACKGROUND: Ischemic stroke (IS) in young adults is increasing in incidence and carries a disproportionate socioeconomic burden. The adoption of reperfusion therapies, particularly mechanical thrombectomy, has transformed stroke care; however, their impact on mortality in this low-risk population remains uncertain. METHODS: We performed a nationwide, population-based retrospective study using the Spanish Minimum Basic Data Set (MBDS), including all hospital admissions for IS in patients aged 18-50 years from 2016 to 2022. Temporal trends in admissions, reperfusion therapies, and in-hospital mortality were assessed. Independent predictors of mortality were identified using multivariable logistic regression. RESULTS: Among 20,533 admissions, the number of hospitalizations increased over time, accompanied by a rise in reperfusion therapies. Mechanical thrombectomy rates nearly doubled from 6.3% in 2016 to 12.1% in 2022 (p < 0.001). Despite this expansion, in-hospital mortality remained low and stable throughout the study period (2.8%). Mortality was independently associated with malignant neoplasm (OR 8.45), followed by orotracheal intubation (OR 4.85), coma (OR 3.73), cerebral edema (OR 2.16), acute kidney injury (OR 1.85), acute respiratory failure (OR 1.38), posterior circulation stroke (OR 1.42), and All Patient Refined Diagnosis Related Groups (APR-DRG) mortality risk level (all p < 0.001). CONCLUSIONS: In young adults with IS, the expansion of reperfusion therapies was not associated with reduced in-hospital mortality, which remained low over time. Malignant neoplasm was the strongest independent predictor of death, followed by acute neurological complications and organ dysfunction. These findings highlight the need for further multicentre clinical research to better understand the causes of death in young adults with IS.
No takes yet. Share an insight, caveat, or question.
Hernández et al. (2026) conducted an observational in Ischemic stroke (n=20,533). Mechanical thrombectomy and reperfusion therapies was evaluated on In-hospital mortality. Mechanical thrombectomy use nearly doubled from 6.3% to 12.1% from 2016 to 2022, while in-hospital mortality in young adults with ischemic stroke remained stable at 2.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: